Logo image of DCTH

DELCATH SYSTEMS INC (DCTH) Stock Price, Quote, News and Overview

NASDAQ:DCTH - Nasdaq - US24661P8077 - Common Stock - Currency: USD

12.11  +0.05 (+0.41%)

After market: 12.11 0 (0%)

DCTH Quote, Performance and Key Statistics

DELCATH SYSTEMS INC

NASDAQ:DCTH (4/25/2025, 8:01:08 PM)

After market: 12.11 0 (0%)

12.11

+0.05 (+0.41%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High16.97
52 Week Low5.12
Market Cap404.84M
Shares33.43M
Float31.46M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE174.6
Earnings (Next)05-08 2025-05-08/amc
IPO10-19 2000-10-19


DCTH short term performance overview.The bars show the price performance of DCTH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

DCTH long term performance overview.The bars show the price performance of DCTH in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of DCTH is 12.11 USD. In the past month the price decreased by -9.63%. In the past year, price increased by 128.49%.

DELCATH SYSTEMS INC / DCTH Daily stock chart

DCTH Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 26.96 223.47B
ISRG INTUITIVE SURGICAL INC 67.35 184.36B
BSX BOSTON SCIENTIFIC CORP 37.74 150.72B
SYK STRYKER CORP 29.95 139.34B
MDT MEDTRONIC PLC 15.76 107.94B
BDX BECTON DICKINSON AND CO 14.74 58.89B
EW EDWARDS LIFESCIENCES CORP 29.25 44.70B
IDXX IDEXX LABORATORIES INC 38.88 35.45B
RMD RESMED INC 25.98 34.64B
GEHC GE HEALTHCARE TECHNOLOGY 15.24 31.33B
DXCM DEXCOM INC 43.43 28.10B
PHG KONINKLIJKE PHILIPS NVR- NY 15.94 23.53B

About DCTH

Company Profile

DCTH logo image Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 96 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Company Info

DELCATH SYSTEMS INC

566 Queensbury Avenue

Queensbury NEW YORK 10019 US

CEO: Gerard Michel

Employees: 76

Company Website: https://delcath.com/

Investor Relations: http://delcath.com/investors/

Phone: 15187438892

DELCATH SYSTEMS INC / DCTH FAQ

What is the stock price of DELCATH SYSTEMS INC today?

The current stock price of DCTH is 12.11 USD. The price increased by 0.41% in the last trading session.


What is the ticker symbol for DELCATH SYSTEMS INC stock?

The exchange symbol of DELCATH SYSTEMS INC is DCTH and it is listed on the Nasdaq exchange.


On which exchange is DCTH stock listed?

DCTH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for DELCATH SYSTEMS INC stock?

12 analysts have analysed DCTH and the average price target is 22.95 USD. This implies a price increase of 89.51% is expected in the next year compared to the current price of 12.11. Check the DELCATH SYSTEMS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is DELCATH SYSTEMS INC worth?

DELCATH SYSTEMS INC (DCTH) has a market capitalization of 404.84M USD. This makes DCTH a Small Cap stock.


How many employees does DELCATH SYSTEMS INC have?

DELCATH SYSTEMS INC (DCTH) currently has 76 employees.


What are the support and resistance levels for DELCATH SYSTEMS INC (DCTH) stock?

DELCATH SYSTEMS INC (DCTH) has a support level at 10.65 and a resistance level at 12.12. Check the full technical report for a detailed analysis of DCTH support and resistance levels.


Is DELCATH SYSTEMS INC (DCTH) expected to grow?

The Revenue of DELCATH SYSTEMS INC (DCTH) is expected to grow by 132.57% in the next year. Check the estimates tab for more information on the DCTH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy DELCATH SYSTEMS INC (DCTH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does DELCATH SYSTEMS INC (DCTH) stock pay dividends?

DCTH does not pay a dividend.


When does DELCATH SYSTEMS INC (DCTH) report earnings?

DELCATH SYSTEMS INC (DCTH) will report earnings on 2025-05-08, after the market close.


What is the Price/Earnings (PE) ratio of DELCATH SYSTEMS INC (DCTH)?

DELCATH SYSTEMS INC (DCTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.98).


What is the Short Interest ratio of DELCATH SYSTEMS INC (DCTH) stock?

The outstanding short interest for DELCATH SYSTEMS INC (DCTH) is 2.74% of its float. Check the ownership tab for more information on the DCTH short interest.


DCTH Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to DCTH. When comparing the yearly performance of all stocks, DCTH is one of the better performing stocks in the market, outperforming 96.6% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

DCTH Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to DCTH. No worries on liquidiy or solvency for DCTH as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DCTH Financial Highlights

Over the last trailing twelve months DCTH reported a non-GAAP Earnings per Share(EPS) of -0.98. The EPS increased by 67.97% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -34.45%
ROE -38.38%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%77.08%
Sales Q2Q%2701.48%
EPS 1Y (TTM)67.97%
Revenue 1Y (TTM)1698.21%

DCTH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to DCTH. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 107.08% and a revenue growth 132.57% for DCTH


Ownership
Inst Owners39%
Ins Owners2.88%
Short Float %2.74%
Short Ratio1.98
Analysts
Analysts85
Price Target22.95 (89.51%)
EPS Next Y107.08%
Revenue Next Year132.57%